For as long as I've been in this industry, we've measured cold chain success at the point of dispensing. Get the therapy to the pharmacy. Get it there on time, at temperature. Hand it off. Done.

That model is no longer sufficient. And for the patients depending on these therapies, it never really was. The direct-to-patient surge has fundamentally redrawn the map.

Today, more than 25 million cold-chain parcels ship directly to patients annually in the U.S. — a number growing at 25-30% year over year. Platforms like LillyDirect and PfizerForAll aren't pilots anymore. They're fully operational ecosystems bundling telehealth, fulfillment, and home delivery into a single experience. The launch of TrumpRx.gov in February 2026 has formalized manufacturer-direct pricing at scale. And the GLP-1 surge alone has strained cold-chain infrastructure in ways the industry wasn't built to absorb.

The last mile hasn't just changed. It has moved. From a loading dock to a front porch. And with that move comes a responsibility our industry hasn't fully reckoned with yet.

The First Moment of Care

When a therapy arrives at a specialty pharmacy or a hospital receiving dock, it enters the hands of trained professionals. Someone checks the temperature log. Someone signs for it. Someone puts it in a calibrated refrigerator.

When that same therapy arrives at a patient's home, none of that is guaranteed.

The patient may not know the package has arrived. It may sit on a porch in Phoenix in August for six hours. The product may not feel cold, and the patient has no way of knowing whether it's still safe to use. The packaging materials may be impossible to dispose of safely. And if something is wrong, the patient often has no clear path to resolution.

This isn't a logistics failure. It's a care failure. And it's happening across hundreds of thousands of shipments every day.

The data is unambiguous: 3% of delivered pharmaceutical product is returned or disposed of daily. $35 billion in therapies are scrapped every year. Only 20% of distributors currently monitor temperature data in transit. These are Healthcare Distribution Association’s (HDA) own numbers, and they were built on a model where most therapies ended their journey at a professional facility, not a residential address.

The direct-to-patient surge has changed the destination. The infrastructure hasn't had a beat to catch up.

Every Stakeholder Is Feeling This Differently

The shift to direct-to-patient isn't a single problem landing in one place. It's a cascade of new pressures, and where you sit in the supply chain determines how it hits you.

Distributors and 3PLs built their models around B2B delivery — bulk pallets to professional receiving docks, SLAs designed for ideal lane performance, carrier metrics that don't capture the "uncontrollable events" that now define residential delivery. The DTP surge has flipped that model. Individual parcels to residential addresses. Patients who aren't expecting a delivery. Porches. Apartments. Rural zip codes where next-day air doesn't mean what it says on paper.

Specialty pharmacies are navigating the most acute version of this challenge. Their patients are often elderly, immunocompromised, or managing complex conditions that make a missed or compromised delivery a clinical event, not just an inconvenience. The question is no longer just whether the therapy arrived. It's whether the patient retrieved it, understood it, and trusted it enough to begin treatment.

Pharmaceutical manufacturers shipping directly to patients and healthcare providers are discovering that the cold chain is now a brand asset. A spoiled shipment at the pharmacy is a replacement cost. A spoiled shipment on a patient's doorstep, at the moment they're starting a new therapy, is a trust deficit that no rebate or reshipment fully recovers. With more than 35 million manufacturer-direct parcels moving annually, the margin for error is compressing fast.

Passive Isn't a Patient Care Standard

The industry has operated on a passive model for years. Standard carrier updates. Data loggers that tell you what happened after the fact. Packaging validated for ideal conditions. SLAs built around best-case scenarios.

That model was designed for a supply chain that ended at a professional facility. It was never designed for the patient.

Active delivery management — predictive modeling, real-time intervention, AI-driven visibility across every shipment — isn't a premium anymore. For the organizations navigating this shift, it's the baseline. Not because regulators are demanding it. Because patients deserve it.

At AeroSafe Global, we've spent more than a decade building toward this moment. Zero cold-chain excursions since 2014. 350 data points per shipment. A closed-loop reuse network operating across 85+ countries. We didn't build that infrastructure for the supply chain. We built it for the patient at the end of it.

But the work starts with an honest diagnosis. Where are your blind spots? Where does visibility end and assumption begin? What does your patient actually experience when your orange box — or your competitor's — lands on their doorstep?

Those aren't rhetorical questions. They're the ones we should all be asking.

Connect with AeroSafe Global